ELAC2/HPC2 involvement in hereditary and sporadic prostate cancer

The ELAC2/HPC2 gene at 17p11 is the first candidate gene identified for human prostate cancer (PRCA) based on linkage analysis and positional cloning (S. V. Tavtigian et al. Nat. Genet., 27:172-180, 2001). A truncating mutation was found in one hereditary prostate cancer (HPC) family, whereas two mi...

Full description

Saved in:
Bibliographic Details
Published in:Cancer research (Chicago, Ill.) Ill.), 2001-08, Vol.61 (16), p.6038-6041
Main Authors: Rökman, A, Ikonen, T, Mononen, N, Autio, V, Matikainen, M P, Koivisto, P A, Tammela, T L, Kallioniemi, O P, Schleutker, J
Format: Article
Language:English
Subjects:
Aged
Aged, 80 and over
DNA - genetics
DNA, Neoplasm - genetics
ELAC2 gene
Exons - genetics
Finland
Genetic Predisposition to Disease - genetics
Genetic Variation
HPC2 gene
Humans
Male
Middle Aged
Mutation, Missense
Neoplasm Proteins - genetics
Polymorphism, Restriction Fragment Length
Polymorphism, Single-Stranded Conformational
Prostatic Neoplasms - genetics
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The ELAC2/HPC2 gene at 17p11 is the first candidate gene identified for human prostate cancer (PRCA) based on linkage analysis and positional cloning (S. V. Tavtigian et al. Nat. Genet., 27:172-180, 2001). A truncating mutation was found in one hereditary prostate cancer (HPC) family, whereas two missense variants, Ser217Leu and Ala541Thr, were reported to be associated with increased PRCA risk in the general population. Here, we screened for mutations of the ELAC2/HPC2 gene in 66 Finnish HPC families. Several sequence variants, including a new exonic variant (Glu622Val) were found, but none of the mutations were truncating. We then analyzed the frequency of the three found missense variants in 1365 individuals, including hereditary (n = 107) and unselected (n = 467) PRCA, benign prostatic hyperplasia (n = 223), and population controls (568 healthy male blood donors). Ser217Leu and Ala541Thr variants carried no significantly elevated risk for HPC or PRCA, although the latter variant was associated with benign prostatic hyperplasia. The previously undescribed Glu622Val variant had a 1.0% population prevalence, but a significantly higher frequency in PRCA cases (3.0% odds ratio, 2.94; 95% confidence interval, 1.05-8.23). We conclude that ELAC2/HPC2 truncating mutations are rare in HPC, but that rare variants of the ELAC2/HPC2 require additional study as risk factors for PRCA in the general population.
ISSN:0008-5472